| Bioactivity | Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons[1]. |
| Invitro | Samatasvir (IDX719) retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals and is not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes[1]. |
| Name | Samatasvir |
| CAS | 1312547-19-5 |
| Formula | C47H48N8O6S2 |
| Molar Mass | 885.06 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Bilello JP, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58(8):4431-4442. |
Samatasvir
CAS: 1312547-19-5 F: C47H48N8O6S2 W: 885.06
Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.